TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30406819

Group type: EXPERIMENTAL
Intervention: High dose of amlodipine (10 mg/day) plus medium dose of ARB (high-AML)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Medium dose of amlodipine (5 mg/day) plus high dose of ARB (high-ARB)
Number of subjects: 67
Study: 28375898

Group type: EXPERIMENTAL
Intervention: High-fidelity virtual reality arthroscopic simulator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bench-top arthroscopic setup
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 40
Study: 26073354

Group type: COMPARATOR
Intervention: Linagliptin 2.5 mg/metformin 850 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Linagliptin 2.5 mg/metformin 500 mg
Number of subjects: 48
Study: 25610905

Group type: EXPERIMENTAL
Intervention: Aerobics exercise for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study: 22927115

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 10
Study: 19534294

Group type: EXPERIMENTAL
Intervention: NPH insulin (10U) injection into the carpal tunnel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 50
Study: 17453298

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m²) every 7 days for 43 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m²) and cisplatin (25 mg/m²)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study: 14760320

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3122
Study: 11452568

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment twice weekly for 8 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Crossover control group receiving acupuncture treatments twice weekly for 8 weeks
Number of subjects: 73
Study: 9549270

Group type: EXPERIMENTAL
Intervention: Tape-recorded message from the attending surgeon
Number of subjects: 60
Study: 8053360

Group type: EXPERIMENTAL
Intervention: Lights on
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lights off
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Participant sex
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Duration of target time
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lighting condition
Number of subjects: 12
Study: 2656774

Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg daily for 3 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol with indomethacin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8
Study: 31134333

Group type: EXPERIMENTAL
Intervention: Mendelian randomisation (MR) analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tests for the null hypothesis of 'no causal effect'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear additive structural model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation of instruments
Number of subjects: 0
Study: 29665733

Group type: EXPERIMENTAL
Intervention: Early surgical intervention (<24 hours post-injury)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Methylprednisolone administration
Number of subjects: 86

Group type: COMPARATOR
Intervention: AIS grade A patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: AIS grade B patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: AIS grade C patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: AIS grade D patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lower motor extremity score (LEMS) change for AIS A
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lower motor extremity score (LEMS) change for AIS B
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lower motor extremity score (LEMS) change for AIS C
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lower motor extremity score (LEMS) change for AIS D
Number of subjects: 86
Study: 27681442

Group type: EXPERIMENTAL
Intervention: Lanicemine 50 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Lanicemine 100 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 302
Study: 25412724

Group type: EXPERIMENTAL
Intervention: Peer-led HIV medication adherence intervention ('Ready')
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy eating control arm
Number of subjects: 20
Study: 22749633

Group type: EXPERIMENTAL
Intervention: Radiation therapy plans compliant with SIOPEN protocol guidelines
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiation therapy plans with justifiable deviations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiation therapy plans with justifiable deviations that might result in adverse effects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiation therapy plans with unjustified deviations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiation therapy plans with no discernible justification
Number of subjects: 100
Study: 21413940

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae derivative AVAC(TM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19188680

Group type: EXPERIMENTAL
Intervention: Low-dose bevacizumab (7.5 mg/kg) plus cisplatin/gemcitabine
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: High-dose bevacizumab (15 mg/kg) plus cisplatin/gemcitabine
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043
Study: 17434891

Group type: EXPERIMENTAL
Intervention: Type-D personality
Number of subjects: 154

Group type: COMPARATOR
Intervention: ICD indication (primary vs. secondary)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Time (baseline vs. 3 months)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Adjusted analysis
Number of subjects: 154
Study: 15715249

Group type: EXPERIMENTAL
Intervention: rK39 dipstick
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional methods (microscopic examinations of bone marrow and lymph node aspirates and immunofluorescent antibody tests)
Number of subjects: 80
Study: 12575547

Group type: EXPERIMENTAL
Intervention: Shuangcao Tuihuang Granule‐1 (SCTH‐1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 8841868

Group type: EXPERIMENTAL
Intervention: Fentanyl 7.5 micrograms/kg and midazolam 0.075 mg/kg administered over 10 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 micrograms/kg and midazolam 0.125 mg/kg administered over 10 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 20.0 micrograms/kg and midazolam 0.200 mg/kg administered over 10 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl 7.5 micrograms/kg and midazolam 0.075 mg/kg administered within 1 minute
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 40
Study: 1703327

Group type: EXPERIMENTAL
Intervention: CHOP‐Bleo regimen (6 courses at 3-week intervals)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Alternate chemotherapy (2 CHOP‐Bleo courses, 2 CMED courses, 2 CHOP‐Bleo courses)
Number of subjects: 115
Study: 7351906

Group type: EXPERIMENTAL
Intervention: High-volume fluid intake (mean excess, 47 ml per kilogram per day)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Low-volume fluid intake (only enough water to meet average estimated requirements)
Number of subjects: 170
Study: 30474990

Group type: EXPERIMENTAL
Intervention: TakeCARE video bystander program
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 165
Study: 28228421

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3
Number of subjects: 118

Group type: COMPARATOR
Intervention: Narrow-band UVB exposure
Number of subjects: 118
Study: 25921377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg)
Number of subjects: 292
Study: 25350959

Group type: EXPERIMENTAL
Intervention: lersivirine 750 mg qd
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: lersivirine 1,000 mg qd
Number of subjects: 97

Group type: COMPARATOR
Intervention: etravirine 200 mg bid
Number of subjects: 97
Study: 22158138

Group type: EXPERIMENTAL
Intervention: 1 set of 10 resistance exercises (RE1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3 sets of 10 resistance exercises (RE3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No exercise (C)
Number of subjects: 10
Study: 20441724

Group type: EXPERIMENTAL
Intervention: Olanzapine (flexible-dose, mean dose 10.8 ± 5.7 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17922461

Group type: COMPARATOR
Intervention: Conventional adjuvant chemotherapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Dose-intensified adjuvant chemotherapy
Number of subjects: 151
Study: 16135353

Group type: EXPERIMENTAL
Intervention: Subtenon bupivacaine 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 40
Study: 12161491

Group type: EXPERIMENTAL
Intervention: GnRH analog therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 10434215

Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane
Number of subjects: 254

Group type: COMPARATOR
Intervention: Low-flow isoflurane
Number of subjects: 254
Study: 8866626

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1636133

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic use
Number of subjects: 90

Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 90
Study: 6735625

Group type: EXPERIMENTAL
Intervention: Gentamicin-metronidazole
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 188
Study: 30537180

Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 236

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Faster aspart and IAsp
Number of subjects: 236
Study: 30103187

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - up to 20 sessions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Attentional Bias Modification (ABM) - 8 sessions
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Attentional Bias Modification (ABM)
Number of subjects: 43
Study: 26718306

Group type: EXPERIMENTAL
Intervention: Depo-Provera (medroxyprogesterone acetate), one injection every 3 months for 6 months (2 doses)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Oral cyclic Norethisterone acetate (NETA), 15 mg daily for 14 days per cycle for 6 months
Number of subjects: 146
Study: 23554029

Group type: EXPERIMENTAL
Intervention: Sinetrol-XPur
Number of subjects: 95
Study: 22584730

Group type: EXPERIMENTAL
Intervention: Sling-constraint group (n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Voluntary-constraint group (n = 23)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups after 12 months follow-up
Number of subjects: 47
Study: 20727460

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus cisplatin and gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin
Number of subjects: 0
Study: 17967583

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT) in addition to conventional treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 200
Study: 15774775

Group type: EXPERIMENTAL
Intervention: Continuous-infusion fluorouracil (CIFU) 250 mg/m²/d for 56 days every 9 weeks for three cycles plus levamisole 50 mg tid for 3 days every other week
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Fluorouracil (FU) 425 mg/m² and leucovorin (LV) 20 mg/m² daily for 5 days every 28 to 35 days for six cycles plus levamisole 50 mg tid for 3 days every other week
Number of subjects: 1135
Study: 12491845

Group type: EXPERIMENTAL
Intervention: Time-limited, group-based problem-solving training intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 46
Study: 9810302

Group type: EXPERIMENTAL
Intervention: Anesthetic cream combined with lidocaine infiltration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 100
Study: 7622850

Group type: EXPERIMENTAL
Intervention: Takeda UA‐751
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Copal UA‐251
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Accutracker 1
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SpaceLabs 90207
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hawksley random‐zero sphygmomanometer
Number of subjects: 28
Study: 2142428

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (600 mg per day for three months)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 7
Study: 627161

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31099657

Group type: EXPERIMENTAL
Intervention: Sunitinib plus cytoreductive nephrectomy (CRN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferred CRN after three cycles of sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate CRN followed by sunitinib
Number of subjects: 0
Study: 26538241

Group type: EXPERIMENTAL
Intervention: Group teletherapy (12 sessions)
Number of subjects: 105
Study: 25770484

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic radical prostatectomy (RALP)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (RRP)
Number of subjects: 510
Study: 22589376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CCX354-C 100 mg twice daily
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: CCX354-C 200 mg once daily
Number of subjects: 160
Study: 21691341

Group type: EXPERIMENTAL
Intervention: Mindfulness group (MG) training
Number of subjects: 75

Group type: COMPARATOR
Intervention: Support group (SG)
Number of subjects: 75
Study: 20017346

Group type: EXPERIMENTAL
Intervention: Spirapryl
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Spirapryl with carvedilol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Carvedilol (monotherapy)
Number of subjects: 86
Study: 16415642

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrinolytic therapy
Number of subjects: 0
Study: 15253850

Group type: EXPERIMENTAL
Intervention: EM practitioners
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-practitioners
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EM practitioners and Non-practitioners
Number of subjects: 17
Study: 11391320

Group type: EXPERIMENTAL
Intervention: Congenital abnormalities present in children with CP (n=192)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Congenital abnormalities present in control children (n=551)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Structural abnormalities of the central nervous system in children with CP
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Non-central nervous system abnormalities in children with CP
Number of subjects: 192
Study: 9578521

Group type: EXPERIMENTAL
Intervention: VGB 100-150 mg/kg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Depot ACTH 10 IU/day
Number of subjects: 42
Study: 7526056

Group type: EXPERIMENTAL
Intervention: moexipril 3.75 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: moexipril 15 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study: 3317356

Group type: EXPERIMENTAL
Intervention: Yeast-derived hepatitis B vaccine (Engerix-B)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 79
Study: 29321134

Group type: EXPERIMENTAL
Intervention: Chronic care model‐based intervention
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study: 26447462

Group type: EXPERIMENTAL
Intervention: Clozapine or Olanzapine
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Olanzapine or Risperidone
Number of subjects: 218

Group type: COMPARATOR
Intervention: HCRTR1 SNPs
Number of subjects: 218
Study: 24065289

Group type: EXPERIMENTAL
Intervention: Internal jugular vein volume flow in patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertebral vein volume flow in patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal jugular vein volume flow in controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vertebral vein volume flow in controls
Number of subjects: 0
Study: 22731679

Group type: EXPERIMENTAL
Intervention: Polymerized type I collagen (PC), weekly subcutaneous intralesional injections ranging from 0.2 mL to 1.0 mL (1.66 mg to 8.3 mg collagen) for 3 months.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Methylprednisolone (MP), monthly subcutaneous intralesional injections of 0.1 mL (20 mg/mL each month) for 3 months.
Number of subjects: 31
Study: 19795993

Group type: EXPERIMENTAL
Intervention: Laser phototherapy (LPT) for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inactive/placebo laser treatment
Number of subjects: 40
Study: 18378030

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study: 16245491

Group type: EXPERIMENTAL
Intervention: Visual feedback via a mirror during movement exercises
Number of subjects: 0
Study: 11954842

Group type: EXPERIMENTAL
Intervention: Closed reduction, primary bone grafting, and external fixation for 3 weeks, followed by a plaster cast for an additional 3 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Closed reduction and external fixation for 6 weeks
Number of subjects: 45
Study: 10525492

Group type: EXPERIMENTAL
Intervention: G1837A allele of the ANP gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G664A mutation in exon 1 of the ANP gene
Number of subjects: 0
Study: 7574508

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg orally every 12 h for 2 days (group 1, 4 h sampling)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg orally every 12 h for 2 days (group 2, 12 h sampling)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg orally every 12 h for 2 days
Number of subjects: 12
Study: 2197377

Group type: EXPERIMENTAL
Intervention: Trained residents
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untrained residents
Number of subjects: 48
Study: 1013693

Group type: EXPERIMENTAL
Intervention: Bendrofluazide and propranolol
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 31567604

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training session
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study: 31504070

Group type: EXPERIMENTAL
Intervention: VR training group
Number of subjects: 57

Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 57
Study: 28582885

Group type: EXPERIMENTAL
Intervention: Nintendo Wii training
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 6
Study: 24668254

Group type: EXPERIMENTAL
Intervention: 12-session coping improvement group intervention
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 12-session interpersonal support group intervention
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Individual therapy upon request
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 295
Study: 23472957

Group type: EXPERIMENTAL
Intervention: Phonological Therapy (PT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Articulation Therapy (AT)
Number of subjects: 14
Study: 21592370

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (33 mg/m2)
Number of subjects: 89

Group type: COMPARATOR
Intervention: 3-weekly docetaxel (100 mg/m2)
Number of subjects: 89
Study: 19808224

Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin (ICO)
Number of subjects: 201

Group type: COMPARATOR
Intervention: 2.5% glucose (GLU)
Number of subjects: 201
Study: 16721678

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control (surgical resection before TME)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) with preoperative therapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) without preoperative therapy
Number of subjects: 161
Study: 14967392

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 0
Study: 11338763

Group type: EXPERIMENTAL
Intervention: Self-Help Interventions (SHIP) for six weeks
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Self-Help Interventions (SHIP)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 169
Study: 9391811

Group type: EXPERIMENTAL
Intervention: Epidural perineural injections
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Epidural perineural injections with triamcinolone (10 mg)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 182

Group type: COMPARATOR
Intervention: Conventional posterior epidural injections
Number of subjects: 182

Group type: COMPARATOR
Intervention: Paravertebral local anaesthetic
Number of subjects: 182
Study: 8198903

Group type: EXPERIMENTAL
Intervention: Group SC (s.c. PCA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group IV (i.v. PCA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 2467095

Group type: EXPERIMENTAL
Intervention: 4 g daily of safflower oil (linoleic acid)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25